Subscribe

DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioral Impairment in the Revised NIA-AA Research Framework

Reprinted with permission. J Geriatr Psychiatry Neurol. 2026;39(3):277–287.* by Rebeca Leon, MSc; Maryam Ghahremani, PhD; Dylan X. Guan, BSc; Eric E. Smith, MD; Henrik Zetterberg, MD; and Zahinoor Ismail, MD

Read More
Digital Resource Center

Upcoming educational events and digital resources related to Alzheimer’s disease Alzheimer’s Association International Conference 2026 July 12–15, 2026 London, United Kingdom * https://aaic.alz.org/   Autoimmune Neurology Conference August 7–8, 2026

Read More
Irene Malaty, MD: Identifying the Appropriate Patients for Subcutaneous Parkinson’s Disease Therapy

Dr. Irene Malaty, from the University of Florida, discusses how to identify patients who may benefit from Vyalev (foscarbidopa/foslevodopa), highlighting key indicators that a patient is ready to transition beyond

Read More
Lessons Learned from Drug Development Programs in Autism: Implications for Future Programs

Innov Clin Neurosci. 2026;23(4–6):9–16. Epub ahead of print. by Gahan Pandina, PhD; William J. Martin, PhD; Christopher Chatham, PhD; Declan Murphy, MD; Jane Myles, MSc; Robert H. Ring, PhD; and

Read More
Part 2—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the neuropsychiatric effects and dyskinesia that patients may experience when taking Vyalev (foscarbidopa/foslevodopa).
Read More
Part 1—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the safety profile of Vyalev (foscarbidopa/foslevodopa), notably injection site reactions and skin considerations.
Read More